Methylene Blue (hydrate)
(Synonyms: 亚甲基蓝水合物,Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate) 目录号 : GC47663
A cationic dye with diverse biological activities
Cas No.:122965-43-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >96.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Methylene blue is a cationic thiazine dye that has diverse biological activities.1,2,3 It inhibits the catalytic function of inducible and constitutive nitric oxide synthases via oxidation of enzyme-bound ferrous iron.1 Methylene blue also inhibits monoamine oxidase (MAO) and increases the activity of mitochondrial cytochrome C oxidase (complex IV).2,3 In vivo, methylene blue stabilizes systemic circulation without increasing peripheral resistance, decreases lipid peroxidation, and reduces anoxic tissue injury in brain and heart in a porcine model of global ischemia and reperfusion injury.1 It inhibits MAO activity in brain and reduces the age-related decline in grip strength and spatial memory in old mice when administered in drinking water at a concentration of 250 μM.2 Methylene blue (15, 30, and 60 mg/kg) also reduces immobility time in the forced swim test in mice, indicating antidepressant-like activity.3 Methylene blue is commonly used to stain cells and tissues in research.4
1.Wiklund, L., Basu, S., Miclescu, A., et al.Neuro- and cardioprotective effects of blockade of nitric oxide action by administration of methylene blueAnn. N.Y. Acad. Sci.1122(1)231-244(2007) 2.Gharib, A., and Atamna, H.Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old miceNeurodegeneration: Theory, disorders and treatments63-85(2011) 3.Harvey, B.H., Duvenhage, I., Viljoen, F., et al.Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analoguesBiochem. Pharmacol.80(10)1580-1591(2010) 4.Hu, X., Laguerre, V., Packert, D., et al.A simple and efficient method for preparing cell slides and staining without using cytocentrifuge and cytoclipsInt. J. Cell Biol.2015:813216813216(2015)
| Cas No. | 122965-43-9 | SDF | |
| 别名 | 亚甲基蓝水合物,Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate | ||
| Canonical SMILES | CN(C)C1=CC2=[S+]C3=C(C=CC(N(C)C)=C3)N=C2C=C1.[Cl-].O | ||
| 分子式 | C16H18N3S.Cl [XH2O] | 分子量 | 319.9 |
| 溶解度 | DMF: 2 mg/ml,DMSO: 2 mg/ml,Ethanol: 3.3 mg/ml,PBS (pH 7.2): 0.14 mg/ml | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.126 mL | 15.6299 mL | 31.2598 mL |
| 5 mM | 0.6252 mL | 3.126 mL | 6.252 mL |
| 10 mM | 0.3126 mL | 1.563 mL | 3.126 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Methylene Blue and ifosfamide-induced encephalopathy: Myth or reality?
J Oncol Pharm Pract 2021 Jan;27(1):143-149.PMID:33153383DOI:10.1177/1078155220971843.
Background: Ifosfamide-induced encephalopathy (IIE) is a rare and serious adverse reaction. Thus far, no standard medication has been documentedto be efficient in the reversal of IIE, and while ifosfamide infusion interruption and hydration are recommended, Methylene Blue (MB) administration remains controversial. Methods: We retrospectively reviewed medical records to assess cases with IIE after ifosfamide infusion. We included all patients having received an ifosfamide infusion during their hospitalization in the medical oncology unit of the National Institute of Oncology in Rabat, Morocco, between September 2016 and September 2017. We subsequently conducted a literature review to determine the role of MB in IIE by searching PubMed using the terms "Methylene Blue" and "Ifosfamide". Results: A total of 88 patients received ifosfamide, and four patients had IIE. Ifosfamide infusion was stopped immediately after the IIE occurrence, and patients underwent renal function correction with hydration. All patients received MB infusion, and three patients had an improvement of their neurological status. As regards the literature review, 34 articles were reviewed and 16 items were included in the review. Overall, 38 (65.5%) patients received MB infusion and 28 (75.6%) patients responded favorably to the treatment. Conclusions: Methylene Blue can be used as a treatment for IIE owing to the severity of the IIE as well as absence of standard medication. Nonetheless, side effects such as serotonergic syndrome should be investigated. More broadly, prospective studies and controlled trials are needed to explore the contribution of MB in IIE management and encourage its use.
Hydrothermal synthesis and Methylene Blue adsorption performance of novel 3D hierarchical Li2Si2O5 hydrate particles
Sci Rep 2020 Mar 26;10(1):5545.PMID:32218513DOI:10.1038/s41598-020-62462-5.
Li2Si2O5 are generally obtained in form of granules with unavoidable impurities including Li2SiO3 and SiO2. Here, we demonstrated a facile hydrothermal route to synthesize novel 3D hierarchical Li2Si2O5 hydrate hollow flower-like microstructures assembled by rod subunits with high purity. The crystal growth was accomplished by complete transformation from poorly crystallized metastable phases formed in the initial stage including Li2SiO3, SiO2 and various Li2Si2O5 hydrate species to Li2Si2O5 hydrate rods. The transformation over many times gave a sustainable high chemical potential to direct the anisotropic growth of Li2Si2O5 hydrate rods with large aspect ratios. Besides, the variation of Li/Si molar ratios confirmed that Li2Si2O5 hydrate rods were obtained only at Li/Si = 1. The perfection and aspect ratio of the rods could be controlled very well by adjusting the hydrothermal temperatures and precursor concentrations. Some new points about obtaining pure phase and anisotropic morphology were discussed, including careful selection of precursors and synthetic method. The obtained novel 3D Li2Si2O5 hydrate structures exhibited a characteristic of mesoporous material and had an excellent adsorption capability of Methylene Blue with high adsorption amount of 49.42 mg·g-1 and color removal of 98.85%, indicating the potential use in wastewater treatment.
Fabrication and Adsorption Behavior of Magnesium Silicate hydrate Nanoparticles towards Methylene Blue
Nanomaterials (Basel) 2018 Apr 24;8(5):271.PMID:29695080DOI:10.3390/nano8050271.
Magnesium silicate as a high-performance adsorption material has attracted increasing attention for the removal of organic dye pollution. Here, we prepared a series of magnesium silicate hydrates (MSH) in a hydrothermal route, and carefully investigated the corresponding adsorption behavior towards Methylene Blue (MB) as well as the effect of surface charge on adsorption capacity. The results show that surface charge plays a key role in the adsorption performance of MSH for MB, a negative surface charge density follows the increase of Si/Mg feeding ratio from 1.00 to 1.75, and furthermore the higher negative charge favors the improvement of the adsorption capacity. Among four investigated samples (MSH = 1.00, 1.25, 1.50, and 1.75), MSH-1.75 has the highest negative surface charge and shows the largest adsorption capacity for MB. For example, the equilibrium adsorption quantity is 307 mg·g−1 for MSH-1.75, which is 35% higher than that of 227 mg·g−1 for MSH-1.00. Besides, for MSH-1.75, the as-prepared sample with negative charge exhibits ca. 36% higher adsorption quantity compared to the sample at the zero point of charge (pHZPC). Furthermore, magnesium silicate hydrate material with Si/Mg feeding ratio = 1.75 demonstrates the promising removal efficiency of beyond 98% for Methylene Blue in 10 min, and the maximum adsorption capacity of 374 mg·g−1 calculated from the Langmuir isotherm model.
Liposomes encapsulating Methylene Blue and acridine orange: An approach for phototherapy of skin cancer
Colloids Surf B Biointerfaces 2022 Dec;220:112901.PMID:36215895DOI:10.1016/j.colsurfb.2022.112901.
Photodynamic therapy uses photosensitizer molecules for the photo-mediated treatment of several diseases such as cancer and skin disorders. However, most of the photosensitizer molecules present problems such as aggregation and low solubility in physiological environments which hinders the treatment efficacy. To overcome these problems, the development of stable liposomes loading photosensitizing molecules as delivery systems can be explored as promising alternatives to enhance cellular uptake and the therapy's efficacy. In this work, liposomes composed by different lipids with or without surfactants were characterized for the encapsulation of photosensitizer molecules such as Methylene Blue (MB) and Acridine Orange (AO). Liposomes were produced by the thin-film hydration method followed by extrusion to reduce particle size and were characterized by Dynamic Light Scattering and Atomic Force Microscopy. Encapsulation efficiency was evaluated as well as the release profile of these molecules from the liposome systems. Cytotoxicity and phototoxicity studies were performed on keratinocytes with and without carcinoma. Results showed that liposome's stability depends on the composition of lipids regardless of the presence of surfactants. Most stable liposomes were those with cholesterol plus the surfactants Span® 80 or sodium cholate that were able to provide higher stability for the liposomes considering the MB and AO encapsulation. Encapsulation efficiency (EE) studies revealed that AO had greater affinity for the vesicles presenting high EE (>98%) while for MB the encapsulation was, in general, moderate (between 63% and 86%). Greater phototoxicity was observed for MET1 squamous cell carcinoma (SCC) cells treated with AO liposomes, achieving similar half-maximal inhibition concentration (IC50) as for the free drug. Finally, two different possible approaches were found, namely, MB-liposomes with potential as a cytotoxic agent for cancer cells; and AO liposomes with a great phototoxicity potential at very low concentrations.
New Twist on an Old Favorite: Gentian Violet and Methylene Blue Antibacterial Foams
Adv Wound Care (New Rochelle) 2016 Jan 1;5(1):11-18.PMID:26858911DOI:10.1089/wound.2014.0593.
Significance: Absorptive antibacterial dressings that assist in controlling bioburden without risks of cytotoxicity or residual absorption can be effectively used for prolonged periods throughout the wound healing continuum. Recent Advances: Until recently, gentian violet and Methylene Blue (GV/MB) antibacterial dressings have been commercially available only in polyvinyl alcohol (PVA) foam; polyurethane (PU) foam bonded with GV and MB with thin film backing is now commercially available. GV/MB PU foam does not require hydration or a necessary secondary dressing. GV/MB PVA and PU foam dressings were recently granted FDA clearance as antibacterial dressings, as opposed to bacteriostatic dressings as previously classified. Within the class of antibacterial dressings, GV/MB foam dressings are of lower cost alternative to silver- or iodine-based antibacterial dressings with no risk of absorption of any of the foam components into the tissues. Critical Issues: Control of wound bioburden levels by antibacterial agents and absorption of excess exudate are crucial in preventing infections that drastically increase the price of wound care. Use of GV/MB dressings may improve wound healing outcomes and decrease overall costs through super absorption, promotion of autolytic debridement, bioburden reduction, ease of use, and decreased dressing change frequency. Future Directions: Evolution in resistant bacterial strains will drive continual changes in advanced wound care products. Demand will increase for economically priced, versatile wound care dressings that assist in debridement, maintain a moist wound environment, absorb and trap bacterial debris, and decrease dressing change frequency.